Forbes Medi-Tech receives Nasdaq Staff Deficiency Letter

Forbes Medi-Tech Inc. (NASDAQ:FMTI) ("Forbes" or "Company") announced today that it has received a Nasdaq Staff Deficiency Letter indicating that it does not meet The Nasdaq Capital Market ("NASDAQ") initial listing standard set forth in Listing Rule 5505 and unless the Company requests an appeal of the Staff's determination, the Company's common shares will be suspended at the opening of business on January 15, 2010, and a Form 25-NSE will be filed with the Securities and Exchange Commission which will remove the Company's common shares from listing and registration on The Nasdaq Stock Market.

The Company may appeal Staff's determination to a Hearings Panel ("Panel"), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, by providing notice of the appeal to NASDAQ no later than 4:00 p.m. Eastern Time on January 13, 2010. The Company will be required to provide a plan to regain compliance to the Panel. A hearing request would stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision.

The Company is considering its options for appeal and will announce if such an appeal is filed.

If the Company does not appeal Staff's determination to the Panel, the Company intends to make application to have the Company's securities eligible to trade on the OTC Bulletin Board.

Source:

Forbes Medi-Tech Inc.

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.